PCSK9 and coronary artery disorder: The demonstration in 2004 that loss of function mutations in PCSK9 lower low-density lipoprotein levels [8] and protect from coronary artery disease [9], and the successful cholesterol-lowering PCSK9 inhibitors consequently developed [10], have served as longstanding exemplars for many complex diseases.